Aclaris Therapeutics (ACRS) Tops Q2 EPS by 1c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q2 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.77 million versus the consensus estimate of $1.28 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
• National Energy Services Reunited (NESR) PT Lowered at Piper Sandler as 'Middle East Slowdown Weighs on Shares'
• Integra LifeSciences cuts 2026 outlook after Cincinnati flood